Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroquinone SCHEMBL9788450 | 0.98 | MAOB (0.50) | MAOBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29392084 | 0.83 | MAOB (0.52) | MAOBKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL178369 | 0.83 | MAOB (0.52) | MAOBKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL288669 | 0.83 | MAOB (0.57) | MAOBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29415192 | 0.83 | MAOB (0.57) | MAOBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16625523 | 0.83 | MAOB (0.52) | MAOBKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL8319257 | 0.82 | MAOB (0.50) | MAOBKDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL1742531 | 0.79 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL487944 | 0.79 | HSD17B10 (0.62) | PDE4APDE4BPDE4CPDE4DHSD17B10 | |
| SCHEMBL2908313 | 0.79 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110240681-A | Composite demulsifying agent and combinations thereof and application | 中国石油化工股份有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-110240675-A | Demulsifier and preparation method thereof and the application in the demulsification of binary combination flooding produced liquid | 中国石油化工股份有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-109929429-A | A kind of cured optical fiber coating coating of Rapid radiating | 浙江福斯特新材料研究院有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-109929430-A | A kind of optical fiber outer coating paint of resistant to hydrolysis | 浙江福斯特新材料研究院有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-104000752-B | Ginger extract for stem cell protection | 西姆莱斯股份公司 | 2018-12-14 | — | — | CN | disclosed |
| US-9343686-B2 | Compound, solar cell module, and solar power generation device | SHARP KABUSHIKI KAISHA (JP) | 2016-05-17 | — | — | US | disclosed |
| US-20150162547-A1 | COMPOUND, SOLAR CELL MODULE, AND SOLAR POWER GENERATION DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2015-06-11 | — | — | US | disclosed |
| US-RE40558-E1 | Therapeutic uses of di-aryl acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| US-6635655-B1 | Agonists or antagonists of peroxisome proliferator-activated receptors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-21 | — | — | US | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150162547-A1 | COMPOUND, SOLAR CELL MODULE, AND SOLAR POWER GENERATION DEVICE | SIK1, CRY1, SIK2 | MAOB 4377/4885PDE4A 3629/4885PDE4B 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.